Durvalumab +/- tremelimumab plus platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

Date
2020
Author
Paz-Ares, Luis G.
Dvorkin, Mikhail
Chen, Yuanbin
Reinmuth, Niels
Hotta, Katsuyuki
Trukhin, Dmytro
Statsenko, Galina
Hochmair, Maximilian
Ozguroglu, Mustafa
Ji, Jun Ho
Voitko, Oleksandr
Poltoratskiy, Artem
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Armstrong, Jon
Byrne, Natalie
Jiang, Haiyi
Goldman, Jonathan Wade
Metadata
Show full item record
URI
http://hdl.handle.net/20.500.12627/5219
Collections